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“Our minds possess by nature an insatiable desire to know the truth.” 
Cicero (106-43 B.C.), Tusculanarum Disputationum I, 18 
 
ABSTRACT 
Multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system, is one 
of the most common causes of neurological disability among young adults. While the etiology 
is unknown, an increasing number of environmental and genetic risk factors is being 
identified. The major contribution to the genetic risk in MS is by alleles of HLA genes, with the 
HLA-DRB1*15:01 allele being the strongest risk factor. At present also more than 100 non-
HLA loci have been identified. 
The main objective of the research presented in this thesis was to study genetic variants and 
their contribution to MS risk.  
In Paper I we investigated whether single nucleotide polymorhisms (SNPs) in the region 
including the IL21 gene, associated with other inflammatory diseases, also contribute to an 
increased risk for MS. Our results confirmed that this locus does most probably not have a 
strong effect, if any, on MS risk. 
In Paper II we studied protein levels of the CXCL13 chemokine as measured in the 
cerebrospinal fluid in relation to a number of MS-associated genetic variants. We found that 
the risk genotypes of HLA-DRB1*15:01 as well as SNPs in the regions of the IRF5, 
OLIG3/TNFAIP3 and RGS1 genes were associated with increased levels of CXCL13 which has 
also been suggested as a biomarker for a more severe disease course of relapsing-remitting 
MS. 
In Paper III we performed an analysis of gene-gene interactions between the currently 
established risk loci in MS and found three pairs of interacting variants with significant 
interaction effects that departed from additivity of the separate effects of the single variants. 
We found interactions between HLA-A*02:01 and HLA-DRB1*15:01, the risk allele of 
rs6677309 and HLA-DRB1*15:01, as well as the risk allele of rs7196953 and HLA-DRB1*03:01. 
The findings suggest that these pairs of risk factors are involved in the same sufficient causes 
for MS.  
In Paper IV we studied cis-regulation of gene expression by MS associated loci and found 
several expression quantitative loci in peripheral blood mononuclear cells. We replicated 
some of them in lymphoblastic cell lines, and observed that one of the eQTLs was also active 
in CD19+, and another in CD4+ cells.  
Replications and functional experiments are needed in order to take the results presented in 
this thesis further in the search for biological pathways involved in MS disease mechanisms. 
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1 INTRODUCTION 
1.1 MULTIPLE SCLEROSIS 
The pathological changes found in multiple sclerosis (MS) were first described in 1868 by the 
French neurologist Jean-Martin Charcot, who identified lesions in post-mortem brains and 
spinal cords of patients with this condition, and therefore called it “la sclérose en plaques” 
(1). Today, this disease is known to be the second leading cause of neurological disability 
after trauma among young adults worldwide (2).   
1.1.1 Epidemiology 
The prevalence of MS varies extensively across different populations and correlation with 
geographical latitude has been observed. High risk areas are found at higher latitudes, and 
in the Swedish population, which is one of the high risk Northern European populations, the 
prevalence has been estimated to 188.9/100,000 individuals, with a female to male ratio of 
2.35:1 (3). Exceptions to the latitude gradient correlation are found in some isolated 
populations such as the Sami in Northern Scandinavia with a very low prevalence of MS (4) 
or the Sardinian population in southern Europe with a high prevalence (5). In the Swedish 
Multiple Sclerosis Registry the mean age at onset of disease was 33.7 years, as reported 
recently (6). 
1.1.2 Clinical manifestations 
Patients initially present with an attack of a neurological symptom or symptoms that can be 
of various kinds such as muscle weakness, numbness, paresthesia, optic neuritis or fatigue. 
A diagnosis of MS is defined based on a set of criteria which are still subject to revisions. 
According to the latest revision of the so called McDonald criteria, MS diagnosis is made if 
there have been more than two attacks with additional evidence of two or more central 
nervous system (CNS) white matter lesions visualized by magnetic resonance imaging (MRI). 
If one of these criteria is missing, additional criteria such as dissemination in time and space 
of visualized lesions and in some cases presence of oligoclonal bands (OCBs) or elevated IgG 
index in the cerebrospinal fluid (CSF) may be used (7). Patients who have experienced an 
attack but do not fulfill all criteria for MS diagnosis are classified as suffering from the 
clinically isolated syndrome (CIS). 
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Approximately 80% of patients diagnosed with MS have a relapsing-remitting MS (RRMS) 
disease course, characterized by bouts of diseases symptoms (relapses) followed by 
complete or partial recovery from symptoms (remissions). Relapse rate, symptoms and 
acquired disability varies to a high degree between patients. With time a majority of RRMS 
patients enter a progressive disease course termed secondary progressive MS (SPMS) in 
which the recovery phases are absent while there is a constant increase in disability. Twenty 
percent have a so called primary progressive MS (PPMS) course with an evident progression 
from disease onset  (8). Disability in MS patients is measured according to the Expanded 
Disability Status Scale (EDSS), which ranges from 0.0 (no neurological symptoms) to 10.0 
(death due to MS) (9). 
OCBs in the CSF can be visualized by using isoelectric focusing on agarose gel followed by 
immunoblotting or immunofixation for IgG. The bands correspond to immunoglobulins 
produced by various plasma cell clones and can be found in the CSF of >90% of all patients 
with MS (10).    
 
 
 
 
Figure 1, Schematic picture of a nerve axon with myelin sheats generated by an oligodendrocyte. Source: 
Wikimedia Commons, http://commons.wikimedia.org/wiki/Category:Images  
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1.1.3 Immunopathology 
The lesions found in the CNS of MS patients arise due to immune attacks on myelin sheaths 
surrounding nerve axons (Figure 1). Disease symptoms are believed to be a consequence of 
compromised action potential conduction due to loss of the isolating myelin, and eventually 
due to axonal loss.  
Under normal conditions, the CNS is isolated from the peripheral immune system through 
the tight blood brain barrier (BBB), however in MS this barrier breaks down, which facilitates 
immune cell trafficking into the CNS. 
Lesions are most often found around blood vessels through which lymphocytes and 
macrophages infiltrate. In active lesions large numbers of myelin debris-containing 
macrophages have been observed (11). Clonally expanded CD8+ T cells are most abundant 
cells in lesions, and CD4+ T cells are present to a lesser degree (12).  γδ T cells (13) as well as 
monocytes have been found, while B cells and plasma cells are less common (14). Based on 
conclusions from the common animal model for MS, experimental autoimmune 
encephalomyelitis (EAE), Th1 cells have previously been thought to drive the inflammation 
in MS (15), however convincing data also support a critical role of pro-inflammatory Th17 
cells in initiation of MS (16, 17). A loss of suppressive activity of Tregs in response to 
autoreactive T cells has been found in patients with MS (18, 19). 
The role of B cells in MS is a matter of current debate and investigation (20, 21). Successful 
clinical trials of B cell-targeting monoclonal antibodies for treatment of MS have 
underscored their importance (22, 23). Lymphoid follicles have been found in the meningeal 
areas in brains of SPMS patients (24), suggesting a persistence of potential antigens that 
drive humoral response (25). 
It is obvious that MS is an inflammatory disease, however it is being debated whether the 
initiating event is a loss of tolerance in the periphery or whether it starts with 
neurodegeneration which leads to inflammation. In an autoimmune scenario, myelin-
specific T cells that have not been eliminated by tolerance mechanisms become activated in 
the periphery and migrate to the CNS where they are reactivated and initiate inflammation. 
A possible mechanism for the peripheral activation of autoreactive cells could be molecular 
mimicry (26). As mentioned earlier, while currently available immunomodulatory 
treatments have proven to be effective in reducing relapse-rate and postponing progression 
in patients with RRMS, there is no treatment for patients with SPMS or PPMS. It has 
therefore been suggested that progressive MS is driven by different mechanisms than RRMS 
(8, 27, 28). 
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1.1.4 Treatments 
There is no cure for MS, however currently available treatments that all target the immune 
system, can decrease symptoms and postpone or prevent progression in many, but far from 
all patients with RRMS. There is no effective treatment for patients with a progressive 
disease course. 
 
IFN-β is the most commonly used treatment, proven to decrease relapse rate with 
approximately 30% (29, 30). The mechanism of the clinical effect of IFN-β is not completely 
understood although several have been proposed (31). The treatment response to IFN-β 
varies. Some patients are non-responders and some develop neutralizing antibodies against 
the drug. Another treatment with similar long-term efficacy to that of IFN-β is Glatiramer 
acetate, a four amino acid long peptide that can bind HLA class II molecules and modulate 
MS through a poorly understood mechanism (32). Natalizumab is a monoclonal antibody 
against the alpha-4 integrin subunit on the surface of lymphocytes. Blocking of this receptor 
for the VCAM-1 adhesion molecule impairs migration of lymphocytes through the BBB. 
Treatment with Natalizumab has showed a striking reduction of relapses and detectable 
lesions by MRI (33). However, progressive multifocal leukoencephalopathy (PML) is a rare 
but extremely serious side effect caused by an opportunistic JC virus infection of the CNS in 
absence of immunosurveillance (34). Other, less commonly used treatments include 
Fingolimod, the first oral MS, mitoxantrone and alemtuzumab, a lymphocyte-depleting 
monoclonal antibody.  Clinical trials for several monoclonal antibodies for MS treatment 
have been performed, such as the B-cell targeting rituximab and ocrelizumab. These showed 
promising results but are not used as standard treatments for MS (22, 23).  
 
1.2 ETIOLOGICAL STUDIES OF MULTIPLE SCLEROSIS 
No single genetic variant or external factor has been identified as the cause of MS, however 
several factors that are associated with increased disease risk on a population level have 
been found. Not all of the risk factors are found in one individual with MS, and many healthy 
persons are exposed to the same risk factors. However in comparison with healthy persons, 
the frequencies of the risk factors are higher among persons with MS. This has led to the 
definition of MS as being a multifactorial, complex disease, meaning that it is likely caused 
by a complex interaction between environmental and genetic factors. Rothman et al have 
proposed a useful conceptual model for causes of multifactorial diseases. This thesis is to a 
large extent influenced by this so called “pie model” or “sufficient-component cause model” 
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(35), visualized in Figure 2. The important message of this model is that there may be many 
different combinations of risk factors that are necessary to act together for development of 
disease. Different individuals with the disease will have different combinations of risk 
factors, and each of those combinations is sufficient to cause the disease. In the following 
sections I will present some of the risk factors that have been identified for MS, with specific 
focus on the genetic risk factors.       
 
Figure 2, Rothman’s pie model. Each pie represents a sufficient cause of disease. Each slice in a pie 
represents a risk factor. In one individual, the combination of all the risk factors present in one sufficient 
cause is necessary for development of disease. Some of the risk factors overlap between different 
sufficient causes. 
 
1.2.1 Environmental factors 
Vitamin D/sunlight deficiency, cigarette smoking, Epstein-Barr virus (EBV) infection and high 
body mass index (BMI) are the environmental risk factors for MS that are backed up with 
most evidence.  
Vitamin D levels and sunlight exposure have been studied due to the latitude gradient of MS 
prevalence. Low exposure to sunlight decreases the endogenous vitamin D production, 
which has been associated with increased MS risk (36). Interestingly, low sunlight exposure 
has been suggested to be a stronger independent risk factor than vitamin D levels (37). 
A number of reports show an association of cigarette smoking (38, 39), EBV infection (anti-
EBNA1 antibodies or mononucleosis) (40, 41)  and BMI (42-44) with MS.    
1.2.2 Genetics 
Undoubtedly genetics play an important role in MS risk. Familial clustering of the disease is 
observed to a certain extent and in the Swedish population the proband-wise concordance 
rate in monozygotic twins has been estimated to 15.38 while it was 1.69 in dizygotic twins. 
The sibling recurrence risk (λs) has been estimated to be 7.1 (6). Moreover, as mentioned 
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earlier, the low prevalence of MS among isolated populations in certain high risk 
environments or high prevalence in lower risk environments, point to the significant 
influence of genetic factors (45-49).  
1.2.2.1 Genetic variation and single nucleotide polymorphisms 
Variation in the human genome, which leads to genetic differences between individuals and 
populations, can be of several different kinds. One example is copy number variations, 
including insertions, deletions, duplications or amplifications of genes, bases or stretches of 
DNA (50). The smallest variations in the genome are called single nucleotide polymorphisms 
(SNPs) and denote a one-base difference at a locus (Figure 4). 
 
Individual 1     A G G T C A T T 
Individual 2     A G G A C A T T 
 
Figure 4, representation of a single nucleotide polymorphism (SNP) with different alleles in two individuals. 
 
 SNPs are very common and widespread across the genome. They can be found in non-
coding sequences as well as in coding sequences. If the base change in a coding sequence 
alters the DNA codon in such a way it leads to an amino acid change in the encoded protein, 
the SNP is denoted as non-synonymous. Conversely, if the SNP does not alter the amino acid 
sequence, it is denoted as synonymous. Importantly, SNPs in non-coding sequences may 
alter loci that are involved in transcriptional regulation or epigenetic control. 
A SNP that is common in a population does not by itself alter biological functions in a 
deleterious way. Variants that have more severe effects or seriously affect survival, will be 
very rare in the population. 
1.2.2.2 Linkage disequilibrium 
During each meiosis several crossing over events (recombinations) take place, thereby 
creating new haplotypes (combinations of alleles on a chromosome). Markers that are 
physically close to each other on a chromosome are more likely to be inherited together 
than more distant markers since the probability of recombination is lower the smaller the 
distance between two markers. Linkage disequilibrium (LD) is a measure of the number of 
recombinations that have taken place in a population. Other factors that are reflected in the 
LD include population history and selection (high LD between two markers might due to 
essential functions attributed to the presence of both markers, which are thus conserved on 
the same haplotype across generations). 
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The basis for the measurement of LD is the calculation of the disequilibrium coefficient (D), 
 
D=PAB-p1q1 
 
where A and B are two different markers, PAB is the frequency of their co-occurrence on the 
same haplotype, and p1 and q1 are the allele frequencies of the markers in the studied 
population. 
Two frequently used measures of LD, D’ and r2, are derived from D. D’ is normalized to the 
theoretical maximum of D which is dependent on the allele frequencies, and can have 
values between -1 and 1. In papers included in this thesis, I have used r2 which is a measure 
of correlation between two markers in a given population. It can have values between 0 and 
1 (where 1 means perfect LD), and is calculated as follows: 
 
r2=D/[PA(1-PA)][PB(1-PB)] 
 
Importantly, due to LD structure in the genome, the association of a marker with disease 
might actually be due to the association with another marker in LD which is the true causal 
variant that contributes to pathogenesis. However, LD structure can also be a very useful 
tool for inference of alleles on a haplotype, called imputation (described in the 
Methodological Considerations section). 
 
1.2.2.3 The HLA region 
The strongest genetic risk factors in MS were already in the 1970’s pinpointed to consist of 
alleles within the region of the major histocompatibility complex (MHC) on chromosome 6 
(51-53). The MHC spans around 7.6 megabases (Mb) and contains 224 identified gene loci 
(54). A large number of these genes play central roles in the immune system, and of these 
the antigen presenting human leukocyte antigen (HLA) genes are the most important. MHC 
genes are subdivided into class I, II and III. Class I and II molecules are expressed on the cell 
surface and present peptides to T cells. Class I HLA genes are expressed on most nucleated 
cells in the human body and present endogenous peptides, which in most cases are self-
peptides, but can also be intracellular pathogens such as viruses. Class II HLA genes are 
expressed on the surface of antigen-presenting cells (APCs) and present peptides from 
extracellular components that have been engulfed and degraded by the APCs.  
The HLA genes are the most polymorphic genes known of in the human genome. According 
to the January 2014 IMGT/HLA Database report (http://www.ebi.ac.uk/ipd/imgt/hla/), 
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8,124 different alleles have been found among the HLA class I genes, being the HLA-A, -B, -C, 
-E, -F, -G protein coding genes and the HLA-H, -J, -K, -L, -P, -T, -U, V, -W, -X pseudogenes. For 
the HLA class II genes, being HLA-DRA, -DRB1 to –DRB9, -DQA1, -DQB1, -DPA1, -DPB1, -
DMA, -DMB, -DOA, -DOB (some of which are pseudogenes), 2,409 different alleles have 
been found. The nomenclature of HLA alleles is periodically revised by the WHO 
Nomenclature Committee since new alleles are constantly being discovered. The current 
nomenclature system is illustrated in Figure 3.   
 
 
Figure 3, Nomenclature of HLA alleles. Figure adapted from http://hla.alleles.org/ 
 
The HLA-DR2 haplotype (DQB1*06:02-DQA1*01:02-DRB1*15:01-DRB5*01:01) stands for 
the strongest genetic association with MS (55). It has been unclear which, if any, of the 
alleles in the haplotype, has an independent effect on MS risk, especially since the 
DQB1*06:02 and DRB1*15:01 alleles are in nearly complete LD in the Caucasian population. 
However, studies in the African American populations, as well as recent large scale studies 
corroborate an independent role of the HLA-DRB1*15:01 allele (56-58). An independent 
strong protective association has been attributed to the HLA-A*02 allele (59, 60), and has 
been confirmed (56, 57). The 2011 MS GWAS confirmed independent effects from the HLA-
DRB1*03:01 and HLA-DRB1*13:03 alleles (56) and other alleles of the HLA-DRB1 and HLA-B 
genes have been added the list of risk loci since (57).  
The association with the HLA locus is a feature that MS has in common with many other 
complex inflammatory diseases, especially those that are defined as autoimmune, thus 
supporting the arguments for classification of MS as an autoimmune disease. 
1.2.2.4 Genome-wide association studies 
As it was early obvious that associated HLA alleles are not sufficient to explain the genetic 
risk for MS, both genome-wide linkage analyses and candidate gene association studies 
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have been undertaken. These were often inconclusive due to lack of power. Alongside the 
development of high throughput genotyping technologies, the genome-wide association 
studies (GWAS) were developed in order to screen for SNP associations with modest effects 
in complex phenotypes across thousands of samples, and the first GWAS was published in 
2005 (61). The GWAS is a hypothesis-free approach in which SNPs that tag LD blocks across 
the genome are chosen to be present on an array, thereby covering the whole genome. 
Allele frequencies at all those SNPs are compared between cases and controls and 
statistically tested for disease association. Importantly, large-sized datasets of cases and 
controls as well as measures for controlling for population stratification are needed in order 
perform well-powered GWAS. The enormous number of association tests made in one 
GWAS makes it almost impossible to establish significant findings if common methods for 
multiple comparison corrections are applied. Based on a correction for the number of 
independent segments in the genome, as well as assumptions regarding the expected 
number of disease-associated loci and approximate numbers of cases and controls in a 
GWAS, a significance cutoff at p<10-8 is applied in GWAS (62). The first MS GWAS was 
performed in 2007 and identified two susceptibility SNPs outside the HLA region, one 
mapping to the IL7R gene and another mapping to the IL2RA gene (63). After the most 
recent GWAS for MS a total of 57 non-HLA loci had been found, and four risk alleles in the 
HLA were confirmed (56) followed by the identification of three additional non-HLA loci 
through a meta-analysis (64). Most of these loci are located in, or close to, immune-related 
genes, which has led to viewing them as potential candidate genes for involvement in 
pathogenesis. An important aspect in association studies such as GWAS, is that only variants 
that are common in the studied population will be possible to detect if they are associated 
with disease. Moreover, GWAS chips are designed to only contain tag SNPs for common 
variants. Rare variants that contribute to disease may be present in subpopulations but will 
not be detected in association studies if the variants are rare enough.       
1.2.2.5 The ImmunoChip Study 
SNP arrays used for GWAS will only measure a subset of all the variants in the genome. 
Disease-associated SNPs found through these studies tag LD-blocks in which any variant 
could be causal in pathogenesis. ImmunoChip is a custom-made SNP microarray designed 
specifically to study loci with significant or suggestive evidence of association with any of 11 
different autoimmune- or inflammatory diseases. One of the goals of the ImmunoChip was 
to fine-map regions where autoimmune- or inflammatory disease associated GWAS variants 
had been found, and another goal was to perform a deep replication of previous GWAS 
results (65). In Paper III and IV of this thesis I have used the 109 most associated 
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susceptibility variants found as a result of the MS-specific analysis which included 14,498 MS 
cases and 24,091 healthy controls (66).  
1.2.2.6 Missing heritability and gene-gene interactions 
As mentioned earlier, the sibling recurrence risk for MS has been estimated to be 7.1 
according to the most recent and extensive study of the Swedish population (6). In the 
ImmunoChip study, a logistic regression model that included the 109 most significantly 
associated non-HLA susceptibility SNPs as well as the four HLA risk alleles established in the 
2011 GWAS for MS (56), was used to estimate how much of the genetic variance can 
currently be explained by these variants. The null model used the relevant principal 
components and accounted for country strata. The conclusion from this analysis was that 
only 18% of the variance in the genetic analysis can be explained by the non-HLA SNPs and 
27% if the HLA risk alleles are added to the analysis. In that analysis a λs of 6.3 was assumed 
(66). In other words, the increased risk for a sibling to an MS patient, who on average share 
50% of the genetic setup, is 6.3 times that of non-related individuals, and only a fraction of 
that risk can be explained by the susceptibility variants we know of today. What about the 
remaining, unexplained fraction of the genetic risk? This is what we call the missing 
heritability.  
There may still be many variants with small effect sizes or rare variants with large effects 
that remain to be identified in MS. Effects of epigenetics such as methylation or parent-of-
origin effects (67, 68) may also form part of the explanation of the missing heritability 
problem found in studies of complex phenotypes in general. Another aspect that might 
contribute to the explanation of missing heritability, is a potentially increased risk due to 
interactions between genetic variants and environmental risk factors. In MS a few studies 
have shown interaction effects between HLA risk alleles and environmental risk factors such 
as smoking and exposure to EBV infection (40, 69). In Paper III of this thesis I have studied 
yet another possible explanation of missing heritability, which is the effect of gene-gene 
interactions.  
There is some confusion regarding the use of terminology and definitions of genetic 
interactions. When the phenotypic expression of a gene is dependent on the presence (or 
absence) of one or several other genes, it is usually called epistasis (70). Sometimes the 
same term is used for merely statistical measures of interaction effects. The term gene-gene 
interaction might in some cases be thought of as a physical interaction between molecules 
in a biological pathway, however it is often used interchangeably with the term epistasis, i.e. 
also when the readout is a statistical measure. I have chosen to use the term gene-gene 
interaction or epistasis according to the definition that two loci interact if their joint effect 
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(in terms of disease risk in this case) is different than the sum or the product of their 
individual effects. Different can mean either more than, or less than the expected joint 
effect. 
Gene-gene interactions can be studied by several different models, and in Paper III we have 
used two: a multiplicative model and an additive model. The multiplicative model assumes 
that the joint effect of two risk factors (in this case genetic variants x1 and x2), is expected to 
be the product of the separate effects attributed to each risk factor: ORX1xORX2. Interaction 
according to the multiplicative model is defined as departure from multiplicativity of effects. 
In the additive model interaction is defined as departure from the expected additivity of two 
separate effects attributed to each genetic risk factor. Estimation of interaction on the 
multiplicative scale is a hypothetical measure since there is no estimation of the OR based 
on individuals who carry the supposedly interacting variants. ORs for each separate variant, 
as well as a third term which is the product of the two ORs, are estimated and fitted into a 
logistic regression model. This method can be useful in order to screen for potential 
interactions to test by comparing cases and controls. When estimating interaction on the 
additive scale, cases and controls carrying all possible combinations of two risk alleles 
studied, are compared to each other, and thus an OR for the co-occurrence of two alleles 
can be estimated. If that OR departs significantly from the additivity of separate risks, then 
these two alleles are supposed to belong to the same sufficient cause as defined by 
Rothman et al (35). 
1.2.3 From genetic variation to function 
1.2.3.1 Transcriptomics and eQTL analyses 
Transcriptomics is defined as the study of the transcriptome, which is the total set of genes 
that have been transcribed to RNA and are present at the time of measurement in a given 
organism, tissue or cell. Transcription of genes is subject to an extremely stringent multilevel 
regulation which is tissue and cell specific, and it changes upon influences from different 
external stimuli. Changes in the transcriptome may also reflect pathological processes that 
are ongoing in cells or populations of cells. Since the advent of high throughput microarray 
technologies in the mid 90-ties (71) tens of thousands of transcriptome studies of different 
human tissues, physiological conditions as well as pathological conditions have been made. 
In studies of MS numerous expression profiling analyses have been performed, mainly in 
immune cells, e.g. comparing MS patients to healthy controls, or patients treated with IFN-β 
to untreated patients. However, differentially expressed genes in immune cells of MS cases 
and healthy controls are seldom found to overlap between different studies, as was 
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systematically reviewed in (72), which has led to the prevailing lack of pinpointed biological 
pathways in MS. As the transcriptome is highly dynamic, in contrast to the mostly static 
genome, common genetic variants that are associated with disease, are also common 
among healthy controls and variation in expression levels will therefore also exist among 
controls. All patients do not share the same susceptibility variants which leads to variation 
among cases, and many genes will be differentially expressed due to the inflammatory state 
in MS.  
Expression quantitative trait loci (eQTLs) are features in the genome that influence the 
expression of genes. For instance, eQTLs can be a polymorphism or indel in a transcription 
factor binding site (TFBS) that will alter the binding of a transcription factor which is 
regulating a certain gene, and thereby affect the expression of that gene. eQTLs can act in 
cis which means that the expression of a nearby gene is affected, or in trans when more 
distant genes, usually on other chromosomes, are affected. The terms are used in a broad 
sense without set distance limits. Cis expression is more often studied compared to tans 
expression due to statistical and computational reasons. In whole-transcriptome studies of 
trans-acting eQTLs the number of SNP-gene expression comparisons will lead to a severe 
multiple testing penalty and the analysis requires large computational capacity.  Progress is 
however made with regard to trans-eQTL analysis including a report supporting spacial 
clustering of trans-eQTLs near the MHC (73). It has been shown that eQTLs are tissue- and 
cell-specific to a large extent (74), although many eQTLs can also be replicated across 
tissues. As a logical consequence of the results obtained from GWAS of many common traits 
and diseases, a need for whole transcriptome eQTL analyses has become evident, and the 
currently available literature comprises several such studies (74-77).   It has now become 
increasingly clear that regulatory variation such as eQTLs is extremely common in the 
human genome and that many known GWAS variants for different traits are eQTLs (78). In 
recent years RNA sequencing (RNA-seq) has emerged as a useful technique for 
transcriptome studies. This high throughput next generation sequencing technique with a 
higher sensitivity and possibilities to study transcription of genes that are not present on a 
microarray (79), was used to study cis-eQTLs in Paper IV in this thesis.  
       
1.2.3.2 Biomarkers 
A biomarker is defined as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or pharmacological 
responses to a therapeutic intervention” (80). The most widely used biomarker in MS is the 
MRI measurement. Other important measurements are the IgG index and analysis of OCBs 
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in the CSF. Several proteins found in the CSF, such as osteopontin (81, 82), matrix 
metalloproteinase-9 (82) and neurofilament (83, 84) have been studied as potential 
biomarkers in MS. In Paper II in this thesis I have used measurements of another potential 
biomarker under investigation, the CXCL13 chemokine, which is more abundant in the CSF 
of patients with inflammatory conditions in the CNS, such as MS, and that could potentially 
be used as a predictor of a severe disease course of MS (85, 86). In many cases, the 
objective of biomarker studies is precisely to find indicators that can be used directly in the 
clinic as an aid in diagnostics or prognosis prediction, however they may also be used as 
important indicators of pathophysiologic mechanisms of the disease.  
1.2.3.3 Bioinformatics and integration of functional data 
Following the completion of the human genome sequence, the ENCODE project is aiming to 
identify all functional elements in the genome (87). A plethora of functional annotations for 
genomic loci is now publicly available through genome browsers, such as 
http://genome.ucsc.edu/ or www.ensembl.org. The annotations are based on analyses 
performed in many different cell lines and primary cells. Of special interest are DNase I 
hypersensitive sites (DHSs), transcription factors found to bind the DNA using ChIP-seq, and 
histone marks specific for enhancers and promoters. Usage of this data can guide follow-up 
studies of disease-associated loci and identified eQTLs.  
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2 AIMS OF THE THESIS 
The general aim of this thesis was to study genetic variants and their contribution to MS risk, 
through these specific aims: 
 
I. To study whether the IL21 locus, which has been associated with other 
autoimmune diseases, is also involved in risk of MS in a Swedish population 
 
II. To study whether different MS-associated loci have a functional influence on 
levels of the potential disease severity biomarker CXCL13 in CSF of MS patients 
and thereby elucidate possible disease mechanisms 
 
III. To study gene-gene interaction between MS-associated loci in order to search 
for causative pathways 
 
IV. To analyze cis-regulation of gene expression by MS associated loci as a way to 
identify genes that are involved in pathogenesis 
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3 METHODOLOGICAL CONSIDERATIONS 
3.1 CASES AND CONTROLS 
DNA, RNA and CSF samples used in the studies presented in this thesis were included in one 
or several of the cohorts described below. 
3.1.1 EIMS 
Epidemiological Investigations in Multiple Sclerosis (EIMS) is an ongoing population based 
incident case-control study (39). Patients and controls have been recruited from all over 
Sweden. Cases fulfil the McDonald criteria (7). Controls are matched for age, sex, and 
residential area. DNA prepared from blood samples from this cohort were included in Paper 
I and III. 
3.1.2 IMSE 
This cohort includes MS patients who are treated with natalizumab and population based 
matched controls (age, sex, area of residence). The study subjects are recruited from all over 
Sweden. (88). In Paper I and III DNA from blood samples from this cohort was used.  
 
3.1.3 BRAIN/STOP-MS 
MS patients in these cohorts were recruited at the Karolinska University Hospitals at Solna 
and Huddinge and all fulfilled either the previously used Poser criteria (89) or McDonald 
criteria for MS (7, 90). The healthy controls are blood donors that visited any of three blood 
donation facilities in the Stockholm area in 2001 and 2004/2005 and were matched by 
ethnicity. The controls were not screened for MS. DNA from this cohort was used in Paper I 
and III. 
3.1.4 GEMS 
All cases in the Swedish MS registry who fulfil the McDonald criteria (7) and who have 
consented to participate in this study are included in GEMS (Genes and Environment in MS). 
The controls are population-based and matched for age, sex and residential area. (91). DNA 
from the GEMS cohort was used in Paper III. 
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3.1.5 STOP-MS 
The STOP-MS cohort includes patients who have been recruited at the Karolinska University 
Hospital (Neurology Clinics of Solna and Huddinge districts), Stockholm, Sweden. The 
controls are not healthy matched controls, but patients with other neurological diseases, 
OND (non-inflammatory), or OND with signs of inflammation (iOND). In this thesis DNA, RNA 
from PBMCs and sorted cells, as well as cell-free CSF from the STOP-MS cohort were used. 
DNA samples were used in all the papers (in Paper I and III only MS cases from this cohort 
were included). In Paper II and IV RNA from PBMCs was used, and in Paper II CSF samples 
from this cohort were analysed.  
 
The studies were approved by the Regional Ethical Board at Karolinska Institutet, Sweden. 
All subjects included in these studies had given their written or oral consent. All samples 
(separation of PBMCs, sorting of cells, DNA/RNA extractions) were prepared using standard 
procedures, described in detail in each of the papers in this thesis when applicable. 
3.2 GENOTYPING 
3.2.1 HLA genotyping 
Classical typing of the HLA-DRB1 and HLA-A genes was performed using sequence-specific 
amplification with the Olerup SSP
®
 low resolution kits (Olerup SSP AB, Stockholm, Sweden) 
(92). Briefly, genomic DNA was mixed with a nucleotide-containing buffer and polymerase 
and added to wells pre-coated with sequence-specific primers. After a polymerase chain 
reaction (PCR) the products were run on agarose gel electrophoresis and visualized with 
GelRed (Biotium, Hayward, CA, USA) staining under UV light. The bands corresponding to 
specifically amplified HLA sequences were compared with a chart used for interpretation of 
the HLA alleles. 
3.2.2 HLA imputation 
Imputation of HLA types based on SNP genotypes from the HLA region typed on the 
ImmunoChip was used in Paper III and IV. The HLA*IMP:02 software (93) was used. In short, 
the SNPs from the dataset to be analyzed are aligned to a reference dataset (in this case the 
HapMap CEU panel), and subsequently the haplotypes are inferred and genotypes are 
imputed.  
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3.2.3 SNP genotyping 
In Paper I and II a subset of the SNPs was genotyped using TaqMan SNP Genotyping Assays 
(Applied Biosystems, Foster City, CA, USA). A TaqMan assay includes probes with 
complementary bases for each allele of the SNP that is being analyzed. The probe is ligated 
to a VIC or FAM fluorophore, specified for each allele, which is coupled to a quencher that 
prevents emission of fluorescence. The assay also contains sequence-specific primers. A PCR 
was performed on genomic DNA samples and once primers and probe were bound and the 
sequence was amplified by the polymerase, the quencher was cleaved off and fluorescence 
was emitted. Allelic discrimination analysis in the samples was done by detection of 
fluorescent signals using the 7900HT Fast Real-Time PCR System and the SDS 2.4 software 
(both from Applied Biosystems, Foster City, CA, USA). 
Another subset of SNPs in Paper I and II was analyzed with matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (Sequenom Inc., San 
Diego, CA, USA) described in detail previously (94). This analysis was performed at the 
Mutation Analysis Facility, Karolinska Institutet. 
The genotypes used in Paper III and IV were analyzed within the ImmunoChip study. DNA 
was hybridized to an Illumina Infinium SNP microarray (Illumina, San Diego, USA) with 
probes for 195,806 SNPs and 718 small indels. DNA samples from the cohorts used in this 
thesis were sent to the Wellcome Trust Sanger Institute and to the Miller School of 
Medicine, University Miami, where genotyping was performed. Quality control (QC) was 
done in Miami. Details on genotyping procedures and quality control can be found in (66). 
 
3.3 EZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
For quantification of CXCL13 in CSF (Paper II) the commercially available Human 
CXCL13/BLC/BCA-1 Quantikine ELISA Kit (R&D Systems, Abingdon, UK) was used according 
to the manufacturer’s instructions. Briefly, a CXCL13-specific monoclonal antibody was pre-
coated onto a microtiter plate, upon which 50 µl undiluted cell-free CSF was added to the 
wells. After washing away unbound substances, an HRP-conjugated monoclonal antibody 
specific for CXCL13 was added. After washing, a substrate solution was added to the wells. 
As a consequence of the enzymatic reaction, color was developed in proportion to the 
amount of CXCL13 bound by the antibodies. The color intensities were measured on a 
spectrophotometer and CXCL13 was quantified. 
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3.4 GENE EXPRESSION ANALYSIS 
3.4.1 Quantitative real-time PCR 
cDNA was prepared using the iScript Reverse Transcription Kit (BioRad Laboratories, 
Hercules, CA, USA). 
IQ SYBR Green Supermix (BioRad Laboratories, Hercules, CA, USA) was used in the real time 
qRT-PCR reactions performed in Paper II and the PCR was run on a BioRad iQ5 iCycler 
Detection System. SYBR Green binds to double-stranded DNA molecules and emits 
fluorescence which is quantified and is proportional to the amount of the product in the PCR 
reaction. Primer specificity was tested with melt curve analyses and PCR products were run 
on agarose gels in order to verify presence of single bands. GAPDH was used as an 
endogenous control. Expression was quantified with either the standard curve method (95, 
96) or with the Delta-Delta Ct (2-ΔΔCt) formula (97). 
TaqMan Gene Expression Assays were used in the qRT-PCR reactions performed in Paper IV. 
The principle for TaqMan chemistry has been described under the SNP genotyping section. 
Fluorescence emitted by probes that have bound to amplified sequences is proportional to 
the amount of PCR products. The PCR was run on the CFX384 Real-Time PCR Detection 
System (BioRad, Hercules, CA, USA), and PCR reaction efficiencies, E (95),(98) were 
calculated using the BioRad CFX Manager System Software. 18S rRNA and HPRT1 were used 
as endogenous controls. Expression was quantified with a modified normalization method 
with two endogenous controls taken into account (99). 
3.4.2 RNA sequencing 
cDNA libraries for RNA-seq were prepared using the Illumina TruSeq kit (Illumina, San Diego, 
USA), according to the manufacturer’s protocol. 
Paired-end sequencing with 100 bp reads on an Illumina HiSeq 2000 machine (Illumina, San 
Diego, USA) was performed with an average sequence depth of 36 million reads per sample. 
All data processing and QC procedures have been described in detail in Paper IV. cDNA 
synthesis and RNA-seq was performed at the Science for Life Laboratory, Stockholm, 
Sweden. 
After mapping of the obtained reads to the H. Sapiens reference genome (NCBI v.37, hg19), 
gene counts were computed (100) and normalized using the trimmed mean of M-values 
(TMM) methodology (101). 
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3.5 STATISTICAL ANALYSIS 
3.5.1 Case-control association tests 
In Paper I and III the - -assoc command in PLINK v.1.07 software (102) was used for 
calculation of odds ratios (ORs) based on chi-square (χ2) tests.  
3.5.2 Meta-analysis 
The meta-analysis in Paper I was performed using a fixed-effect Mantel-Haenszel test with 
the meta.MH command in rmeta package in the free software R (103). 
3.5.3 Quantitative trait association analysis 
In Paper II a quantitative trait association test CXCL13 levels across genotypes (0,1,2) was 
performed with the - -assoc command in PLINK v.1.07 software (102). The command applies 
a Wald test to calculate p-values.     
3.5.4 Interaction analyses 
The gene-gene interaction analyses in Paper III was done using a modified and JAVA-coded 
version of the Gene-Environment and Gene-Gene Interaction Research Application (GEIRA) 
algorithm (104), which estimates interaction using two different methods. Both methods 
are based on calculation of ORs using logistic regression. For estimation of interactions on 
the multiplicative scale, a third term, the interaction term, is added to the logistic regression 
model and tested for significance. For estimation of interactions on the additive scale, the 
ORs are used to calculate the relative excess risk due to interaction (RERI), which in turn is 
used for calculation of the Attributable proportion due to interaction (AP). 
3.5.5 Generalized linear model for eQTL analysis 
In Paper IV a generalized linear model was used to estimate correlation between genotypes 
and gene expression levels, assuming an additive genetic model. Genotypes and covariates 
were included as independent variables and the expression data, the dependent variable, 
was assumed to follow a negative binomial distribution.  
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3.5.6 Multiple comparisons, permutations and bootstrapping 
Several different methods were applied in Paper II, III and IV in order to control our 
statistical measures.  
In Paper II the false discovery rate (FDR) was controlled for by calculation of Benjamini-
Hochberg adjusted p-values using the multtest package in R (103). 
In paper III 1,000 permutations were applied to the data, and the permuted p-values were 
corrected for multiple testing. Corrected permuted p-values correspond to the proportion of 
permuted p-values over all markers that were equal or more extreme than the estimated p-
value. A significance cut-off at p<0.05 was used. 
Permutations were also applied to the data in Paper IV. Moreover the strength of the 
correlation estimates was tested using bootstrapping (resampling over covariate-stratified 
subgroups), and FDR was estimated with a method designed for non-parametric data, 
described in (105).  
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
There were two main reasons that lead us to investigate the IL21 locus and nearby genomic 
region with regard to association with MS: Firstly, our group had previously found a rat EAE 
QTL containing the Il21r and then found a haplotype in the IL21R region that was associated 
with MS (106), which directed our interest towards the IL-21 pathway. Secondly, while 
polymorphisms in the IL21R and IL21 regions are risk loci in systemic lupus erythematosous 
(SLE) (107, 108) they had also been found to associate with high serum levels of IL-21 in MS 
patients, which was predictive of development of a secondary autoimmune disorder post 
treatment with a lymphocyte-depleting antibody. However, there was also a negative report 
from a study in a rather modestly sized Spanish cohort, showing lack of association with MS 
in this region (109). 
 
Results from Paper I 
We thus investigated this by genotyping 12 SNPs in a region comprising the KIAA1109, 
ADAD1, IL2 and IL21 genes, in 2090 Swedish MS cases and 1732 healthy controls. Seven of 
the SNPs were tagging the IL21 gene, three additional SNPs were chosen because they were 
associated with IL-21 serum levels, and two additional SNPs were added in order to fill 
genomic gaps. With this number of subjects we had 93% power to detects an association of 
the same effect size (OR=1.6) that was found for one of the IL21 SNPs in SLE (107), however 
for detection of an OR=1.2, we only had 40% power.  We performed an association analysis 
and did not find significant associations for any of the SNPs with MS, as shown in Table 1 in 
Paper I. We also evaluated whether IL21 polymorphisms are involved in epistatic effects 
that would increase risk for MS only together with the MS associated IL21R polymorphism 
or the HLA-DRB1*15 variant. We did not find any signs of epistasis between these loci. 
Finally, we performed a meta-analysis in which we used allele frequency data for one SNP in 
the published Spanish study (109), that overlapped with one of the 12 SNPs that we had 
typed in the IL21 region. This pooled analysis including 1983 cases and 1682 controls from 
Sweden, and 768 cases and 929 controls from Spain, confirmed the lack of association found 
in each of the separate studies (Figure 5).  
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Figure 5, Meta analysis of rs6822844 in the IL21 region, genotyped in 1983 cases and 1682 controls from 
Sweden, as well as 768 cases and 929 controls from Spain. The pooled analysis confirms the lack of 
association with MS. 
 
Discussion on Paper I 
This paper reports a so called “negative result”. We had a hypothesis, we tested it and could 
not prove it. We also compared our analysis with another, smaller one done before us, and 
confirmed the negative result: An association of variants in the IL21 region with MS could 
not be supported by our data. By reporting this lack of association, we want to contribute to 
the knowledge about genetic risk factors in MS and prevent other researchers from 
spending time and money on trying to find associations with MS in the IL21 region, unless 
they use a rather distant population. Our study had low power to detect a potential small or 
moderate effect in the IL21 region, however later data from the MS GWAS and the 
ImmunoChip study in MS confirmed that IL21 does not harbor any MS risk locus in 
Caucasians (56, 66). Moreover, none of these studies found genome-wide significant 
associations in the IL21R region, a region that our group had previously reported a nominal 
association to (106), thus weakening the probability of the IL21R being a candidate gene in 
MS. However, MS is a highly heterogeneous disease and we cannot exclude that the IL21 
region might be involved in risk in a certain subgroup of patients. 
 
4.2 PAPER II 
The B cell-attracting chemokine CXCL13 has been investigated by quite a few researchers as 
a potential CSF biomarker for MS and other inflammatory conditions in the CNS (85, 86, 
110-113). Although it cannot be used to distinguish between different neuroinflammatory 
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diseases (111), CXCL13 has been shown to have a predictive potential for prognosis in CIS 
and MS, where increased CSF concentration was found more often in CIS patients who 
converted to RRMS, and in MS patients with higher disease activity (85, 86).  
Our aim was to investigate whether some of the genetic variants that were known or 
suggested to be associated with MS at the time of starting the investigation (before the 
latest GWAS from 2011 (56)), also associate with levels of CXCL13 in the CSF. Why would 
that be of interest? From a clinical point of view, such information could reinforce a set of 
markers that could potentially be useful in prediction of prognosis for the patient. From the 
basic researcher’s point of view, combination of genotypic and phenotypic data is useful for 
pinpointing biological pathways in which CXCL13 and the genetic risk variants for MS are 
involved, and thereby guide further investigations of disease mechanisms. 
 
Results from Paper II 
We genotyped HLA-DRB1 and HLA-A, as well as 23 non-HLA SNPs, and measured the 
concentration of CXCL13 in the CSF of 663 individuals diagnosed with MS, CIS, iOND or OND. 
We then used the genotype data for correlation with the CXCL13 levels. We did not find 
significant correlations in the set of patients with iOND and OND (total number=253), while 
five markers (Table 1) showed a significant genotype – CXCL13 level correlation in patients 
with MS and CIS (total number=410). When all disease groups were pooled together, one 
additional SNP was significant for genotype correlation with CXCL13 levels (Table 1). Thus, in 
summary, we found that carrying MS risk genotypes at SNPs in the gene region of (or close 
to) RGS1, IRF5 and OLIG3/TNFAIP3 as well as carrying the HLA-DRB1*15 allele was 
significantly associated with higher levels of CXCL13 in the CSF. These effects were 
pronounced in patients with MS or CIS, and for some of the markers, the significance of the 
association was increased by adding OND and iOND to the analysis. As presented in Table 1, 
and as expected since the variants are associated with MS, genotype frequencies differed 
slightly in MS and CIS patients as compared to OND and iOND. This, together with the fact 
that the group of patients with OND and iOND was smaller than the group with MS and CIS, 
and have lower levels of CXCL13 (Figure 1, Paper II), might explain why significant 
associations between the variants and CXCL13 were not found in the smaller patient group.  
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CXCL13 
correlation
CXCL13 
correlation
CXCL13 
correlation
SNP
Closest 
gene(s) 11 12 22 ADJ. P 11 12 22 ADJ. P 11 12 22 ADJ. P
rs2760524 RGS1 0.02 0.27 0.71 0.02 0.02 0.32 0.65 0.80 0.01 0.24 0.75 0.14
rs9321619
OLIG3/ 
TNFAIP3
0.24 0.47 0.29 0.06 0.22 0.46 0.32 0.80 0.25 0.48 0.27 0.04
DRB1*15 HLA-DRB1 0.07 0.40 0.53 0.02 0.02 0.29 0.69 0.86 0.10 0.45 0.45 0.04
rs4728142 IRF5 0.22 0.49 0.29 0.02 0.24 0.48 0.28 0.80 0.21 0.49 0.29 0.02
rs3807306 IRF5 0.22 0.50 0.29 0.02 0.23 0.47 0.30 0.81 0.21 0.52 0.28 0.01
Genotype 
frequencies
Genotype 
frequencies
Genotype 
frequencies
All diagnoses OND and iOND MS and CIS
 
Table1, Genotype frequencies for the variants that were associated with CXCL13 levels in the different 
patients groups. ADJ. P: adjusted p-value 
 
 
 
Figure 6, Representative graph showing association of CXCL13 levels in the CSF with genotypes at the 
rs3807306 locus. Mean with SD is shown. Differences between groups were tested with the Student’s t-
test. This analysis was done in patients with MS and CIS. 
 
 
Discussion on Paper II 
Our results show an association between genetic susceptibility variants in MS and increased 
CXCL13 levels in the CSF, which in MS patients correlates with the severity of the disease 
course. We do not know whether the associated SNPs are causal in regulating CXCL13 or 
whether they are in LD with causal SNPs or haplotypes. We speculated about potential 
functional connections between the genes located close to CXCL13-associated variants and 
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the chemokine itself. Two studies have suggested a link between HLA-DRB1*15 positivity 
and a more severe disease course of MS (114, 115), which is what could connect this allele 
to the increased levels of CXCL13 (86). RGS1 encodes a protein that attenuates signaling 
through CXCR5, the receptor of CXCL13 (116, 117). IRF5 is a transcription factor that binds to 
interferon-sensitive response elements (ISREs) close to many genes involved in 
proinflammatory responses. Putative ISREs are found in proximity of the CXCL13 gene 
(http://genome.ucsc.edu/), however experimental data confirming a direct regulation of 
CXCL13 by IRF5 is to our knowledge lacking. The SNP rs9321619 maps to an intergenic 
region. The closest genes are OLIG3, involved in nervous system development (118) and 
TNFAIP3 (also called A20) which encodes a negative regulator of NFκB-mediated 
proinflammatory response of TNF (119) and mice lacking A20 in dendritic cells develop 
systemic autoimmunity (120). In view of more recent studies, it should be said that the 
RGS1, OLIG3/TNFAIP3 and IRF5 regions were all included in the ImmunoChip analysis (66) 
and two different SNPs in the RGS1 and OLIG3/TNFAIP3 regions were more significantly 
associated with MS than rs2760524 and rs9321619, respectively. LD between rs2760524 
and the most associated ImmunoChip SNP in the region was however very high (r2=0.959). 
rs9321619 was not typed on the ImmunoChip and the intergenic region where it is located 
had very few SNPs typed on the chip. Using genotype data from the 1000 Genomes, we 
found a SNP that was typed on the ImmunoChip and is in high LD (r2=0.953) with rs9321619, 
while it is in very low LD (r2=0.007) with the most associated SNP on the ImmunoChip, 
mapping nearly 100 kb away from rs9321619. The IRF5 genetic region has not reached 
genome-wide significance for association with MS, only nominal significance in smaller 
cohorts (121). However, in the ImmunoChip study several markers in the IRF5 region 
reached p-values of 10-4. HLA-DRB1*15 certainly keeps being the most associated variant in 
MS, with highly probable, yet largely unexplored functional implications in pathogenesis. In 
Paper II we discussed the functions of the genes that are found closest to the SNPs 
associated with CXCL13 levels, however with the consciousness of the possibility that these 
genes are perhaps not affected by the SNPs. In the eQTL analysis that we have described in 
Paper IV, none of the most disease-associated SNPs in the RGS1 and OLIG3/TNFAIP3 regions 
affected expression of any of these genes when analyzed in PBMCs. The IRF5 region was not 
included in the eQTL analysis (Paper IV) since it was not associated with MS with genome-
wide significance. The HLA-DRB1*15 variant influenced expression of different genes in the 
HLA region (Paper IV). We cannot exclude though, that eQTL effects including these SNPs 
and genes could be found in other cell types which are not present, or very sparse among 
PBMCs. Moreover, it has not been studied whether other types of regulation such as 
splicing affects any of these genes through the SNPs. 
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CXCL13 found in the CSF is for sure a marker of generalized inflammation in the CNS. The 
associations between these genetic risk variants in MS and increased levels of CXCL13 still 
need to be replicated. What remains to be investigated if they become established, is 
whether these variants predispose to more inflammation, or less controlled inflammation, 
which in turn becomes both a risk factor for disease, and a risk factor for a more severe 
disease.  
4.3 PAPER III 
Since only a fraction of the heredity of MS can be explained by all the single genetic risk 
factors that have been identified to date, it is plausible that a part of this missing heritability 
might be explained by effects that are due to interactions between genes. In Paper III we 
aimed to evaluate gene-gene interactions between the currently known MS risk variants in a 
cohort consisting of 2081 cases and 2166 healthy controls of Swedish or Scandinavian origin. 
We used genotypes for the 109 SNPs that were typed within the ImmunoChip Project and 
that showed the most significant independent associations with MS (66), and imputed the 
established MS-associated HLA-DRB1*15:01, HLA-DRB1*03:01, HLA-DRB1*13:03 and HLA-
A*02:01 alleles (56). Using this genotype data we tested gene-gene interactions with two 
different methods: estimation of the product term in a logistic regression model which 
measures interaction as departure from multiplicativity of the effects of two risk variants, as 
well as estimation of the attributable proportion due to interaction (AP) which measures 
interaction as departure from the additivity of effects. 
 
Results from Paper III 
We found significant interactions on the additive scale between presence of HLA-
DRB1*15:01 and absence of the protective HLA-A*02:01, presence of HLA-DRB1*15:01 and 
the rs6677309 risk allele (A) and presence of HLA-DRB1*03:01 and the rs7196953 risk allele 
(A). No interactions on the multiplicative scale remained significant after correction for 
multiple testing. 
Genetic variants AP 95% CI p-value permuted and corrected p-value 
HLA-DRB1*15:01+  
HLA*02:01 - 
0.55 0.28-0.59 1.69*10-8 0.011 
HLA-DRB1*15:01+  
rs6677309_A + 
0.44 0.35-0.75 4.76*10-8 0.013 
HLA-DRB1*03:01+  
rs7196953_A + 
0.71 0.45-0.97 1.01*10-7 0.018 
 
Table 2, Significant interactions on the additive scale between pairs of genetic variants. The estimate AP 
denotes the Attributable Proportion due to interaction  
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Discussion on Paper III 
In all three cases of significant interaction on the additive scale that we report here, a risk 
variant of HLA-DBR1 is involved in the interaction, in two cases it is the HLA-DRB1*15:01 
allele and in one case it is the HLA-DRB1*03:01 allele. It is well known that HLA alleles have 
the strongest effects on MS risk (OR=3.1 and 1.26 respectively, compared to OR<1.20 for 
most non-HLA SNPs). If we hypothesize that MS risk loci interact in causing the disease, and 
that HLA is involved in those interactions, then the probability to detect interactions with 
HLA alleles is higher compared to the probability of finding interactions among non-HLA loci 
with lower ORs. There is no existing method for power estimation in interaction studies 
using departure from additivity, however our results indicate that we do not have enough 
power to detect significant interactions between MS risk loci outside the HLA region.     
Hedström et al have already reported an interaction between presence of HLA-DRB1*15:01 
and absence of HLA-A*02:01 in a smaller subset of our case-control cohort, and they only 
found significant interaction among smokers (69). We again show this interaction with more 
cases and controls included, however we lacked data on smoking habits for a major part of 
the study subjects in our cohort, and therefore we have not stratified for smoking in our 
analysis. Thus, it remains to be investigated in an extended cohort using information on 
smoking habits, whether the interaction can be independent of smoking or not. How the 
HLA-A*02:01 allele confers protection from MS is not known, however studies performed in 
transgenic mice found that HLA-A*02:01 carriers had a dramatic reduction of autoimmune 
response compared to mice carrying the HLA-A*03:01 allele (122) which, even though not 
established as such, is suggested  as a potential risk allele in MS (59, 123). Lacking HLA-
A*02:01 might thus “interact” with HLA-DRB1*15:01 through a lack of reduced immune 
response, and/or by effects from risk alleles in the HLA-A that would not exert effects in 
presence of HLA-A*02:01.  
We identify interaction between rs6677309 and HLA-DRB1*15:01 such that the risk 
associated with having risk alleles at both loci is higher than expected (Figure 2). In fact most 
of the HLA-DRB1*15:01 risk is observed in the presence of the rs6677309 risk allele. The 
rs6677309 SNP, has been found to affect expression of the CD58 gene (124, 125) which 
encodes a molecule that is involved in antigen presentation (126, 127), a function that it has 
in common with the HLA-DRB1 gene that is encoding the beta chain of the HLA class II 
molecule. Expression of HLA-DRB1 is influenced by the HLA-DRB1*15:01 allele, as shown by 
us (Paper IV) and others (125, 128). Conversely, we did not observe an association with 
rs6677309 genotypes and CD58 expression in Paper IV when analyzed in PBMCs. Even 
though our result has to be interpreted with caution due to the small number of individuals 
in the reference group (negative for both risk factors) used in the interaction analysis, the 
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reported functional consequences encourage experimental tests of the interaction between 
HLA-DRB1*15:01 and rs6677309 A allele (Figure 7). 
 
 
Figure 7, Effects (ORs) of presence of the single variants HLA-DRB1*15:01 and rs6677309_A, and their 
interaction. 
 
 
In contrast to HLA-DRB1*15:01 there are, to our knowledge, no published reports regarding 
the influence of the HLA-DRB1*03:01 allele on expression of HLA genes, however in Paper IV 
we found that several HLA genes were affected both in PBMCs and in LCLs, and interestingly 
the effects were consistently opposite to those of the HLA-DRB1*15:01 allele. We observe 
an interaction of the HLA-DRB1*03:01 with the risk allele of rs7196953. No functional 
studies regarding rs7196953 have been reported. It is located in between the MAF gene and 
the gene and the DYNLRB2 gene and does not map to any DHS that can be found in the 
public data provided by the ENCODE project (87).  
Our goal is to understand more of the role of genetics and biological pathways involved in 
pathogenesis with the help of gene-gene interaction studies, however as I pointed out in the 
beginning of this discussion, these analyses probably require much more statistical power. 
Moreover, variants with lower effects, not reaching genome-wide significance or even any 
variant in the genome (not found in association studies) could be involved in interactions 
that lead to disease. Since we cannot calculate power, it is not known how many cases and 
controls that are needed to screen for such interactions, only that it has to be more than in 
the studies performed to date. Another major limitation in the screening for interacting loci, 
is the current technology and computational resources which make large numbers of 
statistical tests with the necessary number of permutations or resamplings rather infeasible. 
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One possible strategy is to allow less stringent significance thresholds and choose sets of 
potentially interacting variants with reported functions, and turn to experimental 
validations. 
When it comes to studying interactions on a multiplicative scale, we are actually studying a 
hypothetical interaction, since we do not measure whether both risk alleles are carried 
together more often in those who are cases compared to those who are controls. We only 
measure the OR for each separate variant, and then measure whether the slope of the 
regression curve increases dramatically (more than expected) when the two ORs are 
multiplied with each other. If that is the case one can use the case-control cohort to test 
whether the simultaneous presence of the two risk factors is significantly more frequent 
among cases. We did not find interactions on the multiplicative scale which held for multiple 
testing corrections, and have therefore not investigated them further in the present study. It 
would however be interesting to explore the potential multiplicative interactions in the 
future, using an extended case-control cohort. 
 
4.4 PAPER IV 
To our knowledge there is still no published study in which the currently most up-to-date list 
of MS-associated loci have been evaluated as potential eQTLs. We hypothesized that a 
fraction of these risk loci are eQTLs for one or several genes, given that eQTLs are very 
common in the human genome (78) and most of the risk loci are not coding variants, and 
given that dysregulation of gene expression might underlie disease development. As 
described in the introduction, eQTLs can act in trans or cis, and we decided to study cis 
regulation within the limits of an 800 kb genomic window centered around each associated 
locus. This restriction reduces the probability of observing false positive associations 
compared to a case where expression of all the genes in the genome would be tested for 
both trans and cis regulation by the MS risk loci. Moreover, based on previously reported 
observations, most cis-eQTLs or DHSs were found approximately at 400 kb distance from 
the affected gene (129, 130).     
 
Results from Paper IV 
We performed RNA-seq in PBMCs from 183 individuals, diagnosed with MS, clinically 
isolated syndrome or other neurological diseases. We used genotypes from the 
ImmunoChip Project for 109 SNPs with the strongest independent associations with MS, and 
HLA-types that were imputed using ImmunoChip data. In the eQTL analysis we tested for 
association of the 109 SNPs and four MS risk alleles in the HLA region, with expression levels 
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of the genes in the established genomic window. By using a regression model, we could 
correct for relevant covariates such as gender, diagnosis and batch of preparation in the 
analysis. We used a set of criteria to choose results that we considered to be significant and 
that we wanted to validate. We chose 20 non-HLA loci that influenced the expression of in a 
total of 28 genes and three HLA variants that influenced the expression of seven different 
genes, however five of them were influenced by two different alleles.  
 
 
SNP Closest gene(s) 
Genotype-gene 
expression 
association 
Significant in cell 
type(s) 
rs11587876 DDAH1 WDR63 PBMCs 
rs3748817 MMEL1 MMEL1 PBMCs 
rs7595717 CNRIP1 (dist=40294), PLEK (dist=4845) PLEK PBMCs, CD4+ 
rs842639 FLJ16341 AHSA2 PBMCs 
rs9989735 SP140 SLC16A14 PBMCs 
rs1920296 IQCB1 IQCB1 PBMCs, LCLs 
rs7665090 
  KRT8P46 PBMCs 
NFKB1 (dist=13144), MANBA (dist=1040) RP11-10L12.6.1 PBMCs, LCLs 
  MANBA PBMCs, LCLs 
rs71624119 ANKRD55 ANKRD55 PBMCs 
rs11154801 AHI1 AHI1 PBMCs, LCLs 
rs941816 PXT1 
ETV7 PBMCs 
RAB44 PBMCs 
rs1021156 PKIA (dist=58302), ZC2HC1A (dist=2478) 
FAM164A 
(ZC2HC1A) 
PBMCs, LCLs 
rs694739 PRDX5 (dist=7938), CCDC88B (dist=10457) AP003774.1.1 PBMCs, LCLs 
rs11052877 CD69 
RP11-726G1.1.1 PBMCs 
CLECL1 PBMCs, LCLs 
rs12296430 LTBR (dist=2768), CD27-AS1 (dist=44667) ZNF384 PBMCs, LCLs 
rs201202118* 
  METTL21B PBMCs 
TSFM XRCC6BP1 PBMCs 
  AVIL PBMCs 
rs1886700 CDH3 CDH1 PBMCs 
rs4780346 CLEC16A (dist=12760), SOCS1 (dist=59468) RMI2 PBMCs 
rs12946510 GRB7 (dist=8839), IKZF3 (dist=1591) 
GSDMB PBMCs 
ORMDL3 PBMCs, LCLs, CD19+ 
rs4794058 MRPL45P2 (dist=27112), NPEPPS (dist=11346) 
TBKBP1 PBMCs, LCLs 
MRPL45P2 PBMCs, LCLs 
rs470119 TYMP CPT1B PBMCs 
 
Table 3, List of the most significant non-HLA SNP-gene expression associations presented in Paper IV 
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HLA variant 
Genotype-
expression 
association 
Significant in 
cell type(s) 
HLA-
DRB1*15:01 
(presence) 
HLA-DQB1 PBMCs, LCLs 
HLA-DRB5 PBMCs, LCLs 
HLA-DRB1 PBMCs, LCLs 
HLA-DQB1-AS1 PBMCs, LCLs 
HLA-DQA1 PBMCs 
HLA-
DRB1*03:01 
(presence) 
HLA-DQB1 PBMCs, LCLs 
HLA-DRB5 PBMCs, LCLs 
HLA-DRB1 PBMCs, LCLs 
HLA-DQB1-AS1 PBMCs, LCLs 
HLA-DQA1 PBMCs 
HLA-A*02:01 
(absence) 
HCG4 PBMCs, LCLs 
HLA-J PBMCs, LCLs 
 
Table 4, List of the most significant HLA variant-gene expression associations presented in Paper IV. 
 
In the second phase of the project, we tested these potential eQTLs in an independent 
public dataset consisting of genotype and RNA-seq data from lymphoblastic cell lines from 
232 individuals. We replicated 9 significant non-HLA eQTLs which affected the expression of 
in total 11 genes, as well as the three HLA variants and six genes influenced by them. In 
addition, we used an additional patient cohort (n= 59) to test three eQTLs in sorted PBMCs. 
Due to low minor allele frequencies for many of the SNPs, or very low expression levels, we 
could only test three of the SNPs in sorted PBMCs, where we were limited by the low 
number of samples and detection limits of qRT-PCR, the method we used for expression 
quantification in sorted PBMCs. We replicated two of the three eQTLs tested in sorted 
PBMCs. A summary of all significant is found in Table 3 and 4. 
 
Discussion on Paper IV   
In this paper we have used a hypothesis-free approach in the sense that we have included 
all genes present in the 800 kb windows in our eQTL analysis. 
We performed our initial analysis in primary immune cells, which gave us the advantage of 
avoiding potentially cell-line specific effects, while the disadvantage lies in that PBMCs 
contain a mix of different cell types. Using cells from MS patients as well as patients with CIS 
and OND gave us the possibility to compare effects in MS patients with non-MS, while we 
had to correct for the different diagnosis groups in the regression analysis, thus reducing 
power. We could however conclude that most of the eQTLs observed in our study were 
independent of disease state. 
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In discussing the results from Paper IV, we must necessarily make some statistical 
considerations. Our data was influenced by several factors which we were aware of and 
intended to control for. With the help of a principal component analysis (PCA), we identified 
three factors among variables that we had data for, which significantly influenced variance 
in our data: batch of cDNA library preparation, gender of the patient and age at sampling. 
We corrected for these factors in the regression analysis by using them as covariates. In 
addition, we included disease state and interferon treatment as covariates, due to their 
likely influence on gene expression, especially of immune related genes. As commonly 
observed in gene expression studies, there was a widespread presence of outliers in the 
expression data for each gene. The outliers did not correspond to the same individuals 
across all genes. We used permutations in order to avoid false positive results that are in 
fact driven by outliers. Also because of the outliers, we did not know how robust our 
correlation estimates were and therefore we applied bootstrapping. Finally, in order to 
account for multiple testing, we applied a non-parametric FDR, which was based on the 
correlation estimates. Based on the FDR analysis, very few associations would be accepted 
at an FDR<0.25, on the other hand the lower FDRs more often correlated with high beta 
estimates. The criteria which we set for choosing associations to validate, prioritized a low 
permuted p-value over a low FDR or a high beta estimate. We assumed that small but 
robust effects (low beta values with low corresponding p-values) were likely to be true, even 
though they did not correspond to an acceptable FDR. However, to be able to evaluate 
whether strong effects (high beta estimates and low FDRs) would be replicated, we included 
some associations based on the latter criteria in the validation analysis. A detailed 
description of the validation criteria is found in Paper III. Most of the replicated SNP/HLA-
variant gene expression associations corresponded to high FDRs (>0.25), low permuted p-
values and varying beta estimates, thus confirming our assumptions, however without 
discarding the potential significance of high effects. We can also draw the conclusion that a 
thorough method for calculation of the FDR in this type of data is needed.        
Many eQTLs are cell type specific or have more pronounced effects in specific tissues (74) 
and we believe that the lack of replication in LCLs of some eQTLs that were significantly 
associated in PBMCs reflect this cell specificity, which is also supported by one of the eQTLs, 
rs7595717 which was significantly associated with expression of PLEK in PBMCs and CD4+ 
cells, but not in LCLs, CD8+, CD19+ or CD14+ cells. We cannot exclude however, that the eQTL 
was active in any other of the sorted PBMC cell types, since the power in that analysis was 
very limited.   
The genes that we have found in this study are involved in a wide range of different 
biological processes. Some of them have characterized functions in immune cells or 
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processes, such as CLECL1 (131), TBKBP1 (132, 133) and ORMDL3 (134). Several genes are 
pseudogenes or genes with unknown functions, while other genes, such as AHI1 (135, 136) 
and MMEL1 (137-139), seem to have functions described in different tissues and processes, 
including the CNS.   
Expression of different HLA genes in relation to MS risk alleles require further investigation 
and replications before conclusions can be drawn, due to a partial lack of agreements 
between previous studies (refs). 
Our findings show that several of the genetic variants associated with MS, affect the 
expression of genes that are potentially involved in the pathogenetic mechanisms. These 
results warrant further functional studies of the eQTL-regulated genes and the involved 
biological pathways, with focus on specific cell types.    
 
 
4.5 SUMMARY OF FINDINGS 
 
 We have shown that the IL21 locus in not a major risk locus in MS in the Swedish 
population. 
 
 We have found four MS-associated genetic variants that potentially influence 
pathways that lead to increased levels of the CXCL13 chemokine in CSF. 
 
 We report three pairs of genetic variants that show interaction measured as 
departure from additivity of individual variant effects. 
 
 We have identified 20 non-HLA MS risk loci and three HLA variants that in PBMCs 
show eQTL effects influencing expression of 28 non-HLA genes and seven HLA genes, 
respectively. We show that seven of the non-HLA eQTLs were also active in LCLs, one 
was active in CD19+, and another in CD4+ cells. 
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5 CONCLUDING REMARKS 
In this thesis I have focused on the study of genetic loci that are associated with an 
increased risk of MS. When I started out my thesis work, less than 10 non-HLA risk loci in MS 
had been established (63, 140-142), and in screens for association with disease, the 
candidate gene approach was more widely used than today. Throughout these years new 
loci have been added to the list of risk variants, several associated regions have been fine-
mapped and we now have increased possibilities for functional investigations of these loci. 
The studies included in this thesis reflect this development to some degree.  
 
Throughout my work I have been searching for clues about which biological pathways to 
study in order to increase the understanding of MS disease mechanisms. For this I have used 
different strategies: candidate gene approach (Paper I), using biomarker data together with 
genetic associations to track back to potential disease mechanisms (Paper II), gene-gene 
interaction analysis (Paper III) and finally eQTL analysis (Paper IV). 
In what way has this thesis contributed to the field of genetic research in MS? Hopefully, 
Paper I has helped to encourage efforts to search for other major effect candidate genes 
than IL21. Paper II-IV have resulted in interesting findings that prompt replication and/or 
functional investigations. We have found genetic associations with CSF levels of the CXCL13 
chemokine which are elevated when there is ongoing inflammation in the CNS and correlate 
with increased disease activity in MS (Paper II). We have found risk alleles that are present 
together in MS cases more often than expected, thus being said to interact and likely to be 
present in the same sufficient cause for MS (Paper III). We have identified several risk loci 
that are eQTLs, some of which were replicated from previous studies, while several are new 
(Paper IV). In this thesis, I have only been able to speculate about functional roles in MS 
pathogenesis of candidate genes found through the studies, however I have not yet had the 
possibility to test their functions experimentally. This will be the subject of my future 
perspectives. 
 
Why is it so important to understand disease mechanisms? Is it not enough that there are 
quite efficient treatments for MS today, even though we do not know exactly why they 
work well? Unfortunately the treatments do not work well for all persons with this highly 
heterogeneous disease, and are moreover associated with increased risk for serious adverse 
events. By studying disease mechanisms we hope to find new, personalized and more 
effectively targeted treatments, as well as ways to prevent disease.  
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We are still far from understanding how, and through which functions genetic variation 
contributes to MS, but hopefully the results presented in this thesis may be of help for 
future studies in this direction.    
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6 FUTURE PERSPECTIVES 
There are many things that remain to be analyzed in the data that I have worked with in this 
thesis, and there are even more analyses and experiments that I would like to do as a 
follow-up to my findings.  
 
As I mentioned earlier, further genetic studies of the IL21 region do not seem to be of 
interest at this stage given the knowledge that we have about genetic influences in MS, 
although it cannot be excluded that we would go back and explore its function in a subgroup 
of patients in the future. 
  
To follow up the study in Paper II, it would in the first place be of interest to analyze levels of 
CXCL13 and other potential CSF biomarkers in relation to an updated list of MS risk loci in an 
extended cohort with a greater number of individuals included. In parallel, our RNA-seq data 
could be used to evaluate whether differences in expression of the CXCL13 gene can be 
observed in PBMCs in relation to genotypes from the ImmunoChip data. It has been shown 
that CXCL13 in the CSF is mainly produced by infiltrating monocytes to the CNS, and 
probably even more if they are differentiated into macrophages (110), therefore an eQTL 
study in monocytes (preferably purified from the CSF) and macrophages would be of great 
interest. 
  
The findings from Paper III should be replicated in an independent and larger cohort, which 
is especially important in order to validate the suggestive interaction between HLA-
DRB1*15:01 and the rs6677309 A allele, since the reference group (negative for both risk 
alleles) was very small. The results in Paper III can be followed up by studying expression 
levels of HLA-DRB1 and other HLA class II molecules together with the expression of CD58 in 
relation to the SNP genotypes, and evaluate functional consequences such as T cell 
proliferation and induction of Tregs. 
 
To follow up on the results presented in Paper IV, most importantly, the eQTLs should be 
validated in different cell types. Subtypes of immune cells are of primary interest, and most 
easy to access. However, other tissues, in particular cells in the CNS, should not be 
neglected. These tissues are obviously very difficult to access for human studies and 
therefore transgenic animal models will be useful. The animal models should be used to 
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evaluate normal functions of the candidate genes, as well as their functions in disease 
models for MS, such as the EAE. 
  
The fact that we have not detected eQTL effects for some genes that have been reported by 
others, such as the CD58 gene or CYP27B1, underscores the importance of future cell type-
specific eQTL analyses, and also that other genes, with less significant expression 
associations to the MS SNPs in our data, should be considered in future analyses. The RNA-
seq data produced for Paper IV can also be used to study how MS variants influence the 
expression of transcript isoforms by quantification of exon expression.      
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